Chronic Leukemia Perspective

 
 
  • ASHCAR T-Cell Therapy at ASH 2015: What's Hot A preview of the most important research on CAR T-cell therapy at the ASH 2015 annual meeting.
  • What to Expect in Hematologic Malignancies   Dr Bruce Cheson previews the most important trials being presented at ASCO 2015 on Hodgkin's and non-Hodgkin's lymphoma, acute and chronic leukemia, and multiple myeloma.
  • Top News From NCCN 2015: Slideshow Highlights include guidance on the treatment of chronic myelogenous and lymphocytic leukemias, genomic testing for early breast cancer, and lymph node biopsy for melanomas.
  • 'Emperor' in Close-Up: A Talk With the Director   Dr Harold Burstein gets an oncologist's behind-the- cameras view of 'Cancer: The Emperor of All Maladies,' from Barak Goodman, director of the Ken Burns documentary.
  • Today's Cancer Research Pioneers More than 50 years after the introduction of chemotherapy, a new wave of researchers seek to radically advance cancer treatments.
  • NephMadness 2015: Onconephrology Learn about key concepts that overlap oncology with nephrology, and then use your knowledge to pick the 'winners' in the NephMadness Tournament.
  • CLL: It's the Best -- and Most Confusing -- of Times   Dr Bruce Cheson and Dr Susan O'Brien discuss data presented at the 2014 ASH meeting on chronic lymphocytic leukemia, with a focus on the CLL10 trial as well as ibrutinib, idelalisib, and ADT-199.
  • The Year in Hematologic Malignancies Experts in hematologic malignancies comment on the most important developments and practice-changing clinical trials of 2014.
  • ASH 2014: If You're Going to San Francisco…   Dr Bruce Cheson previews important data being presented at the upcoming ASH 2014 meeting, including studies of CLL, Hodgkin lymphoma, and the role of interim PET scans in large cell lymphoma.
  • What's New: Imaging in Lymphoma   Dr Bruce Cheson breaks down new consensus recommendations on the role of imaging in staging and response assessment for lymphoma.
  • The 'Fab Five' Rock Lymphoma   Dr Martin Dreyling reviews recent data in lymphoma indicating that the command performance of five biologic agents do all but lock the door on chemotherapy and throw away the key.
  • ESMO Guideline for Mantle Cell Lymphoma ESMO recently published its guideline for mantle cell lymphoma. Author Martin Dreyling highlights some of the key, evidence-based recommendations.
  • CAR T Cells: A Look Under the Hood and Down the Road Lost your way in immunotherapy? Dr. Mark Adler provides clinicians a roadmap for navigating cancer immunotherapy and takes one of the most promising approaches -- CAR T cells -- for a test drive.
  • CLL's 'Very Unusual Year'   Dr. Bruce Cheson discusses how to choose among the new, exciting options available for the treatment of chronic lymphocytic leukemia: obinutuzumab, ibrutinib, and idelalisib.
  • Ibrutinib Stands Center Stage in CLL   Dr. John Gribben highlights new data on single and combination therapies for CLL as presented at EHA 2014.
  • Top News From ASCO 2014: Slideshow Highlights include practice-changing research on breast and prostate cancer, and 2 targeted therapies that are equally effective in metastatic colorectal cancer.
  • Ibrutinib Results RESONATE in Refractory CLL   Drs. Bruce Cheson and Myron Czuczman discuss lymphoma and leukemia highlights from ASCO 2014, including the RESONATE and SEXIE trials and emerging antibody-drug conjugates.
  • ASCO® 2014: Aiming at Cancer’s Achilles Heel   Four leading oncologists discuss the top studies from ASCO 2014 and how immunotherapy is reshaping cancer care and practice.
  • What to Watch in Lymphoma, Leukemia   Dr. Bruce Cheson reviews a wealth of practice-changing and practice-confirming studies from the lymphoma and leukemia sessions at ASCO 2014.
  • Mantle Cell Lymphoma -- Still More Questions Than Answers Mantle cell lymphoma remains a clinical challenge. Dr. Julie Vose discusses current evidence on treatments, differences in strategy, and whether emerging novel therapies could improve outcomes.